Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657179 | 0.89 | ALDH1A1 (0.65) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL8678546 | 0.86 | KMT2A (0.60) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL4779659 | 0.83 | ALDH1A1 (0.72) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL5438077 | 0.81 | ALDH1A1 (0.59) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL19794294 | 0.79 | ALDH1A1 (0.62) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL739728 | 0.79 | KMT2A (0.53) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL24540417 | 0.79 | — | — | |
| SCHEMBL25009512 | 0.79 | ALDH1A1 (0.80) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL27090339 | 0.79 | ALDH1A1 (0.80) | KMT2AALDH1A1POLBTSHRCA12 | |
| SCHEMBL2062301 | 0.78 | KMT2A (0.40) | KMT2AALDH1A1POLBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| WO-2022164997-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| WO-2012129322-A1 | IMPROVED SYNTHESIS OF TETRABUTYLAMMONIUM BIS(FLUOROSULFONYL)IMIDE AND RELATED SALTS | TRINAPCO, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-2500368-A2 | Catalyst and process for producing a rigid polyurethane foam | Tosoh Corporation (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009149508-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-17 | — | — | WO | disclosed |
| US-20070043132-A1 | Catalyst and process for producing a rigid polyurethane foam | TOSOH CORPORATION (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20040082465-A1 | Catalyst and process for producing a rigid polyurethane foam | TOSOH CORPORATION (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1382624-A1 | Catalyst and process for producing a rigid polyurethane foam | Tosoh Corporation (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | KMT2A 543/4885ALDH1A1 717/4885POLB 3600/4885 |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | KMT2A 2725/4885ALDH1A1 4006/4885POLB 1349/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885ALDH1A1 3742/4885POLB 1230/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | KMT2A 2793/4885ALDH1A1 3742/4885POLB 1230/4885 |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | KMT2A 845/4885ALDH1A1 4002/4885POLB 4507/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | KMT2A 2793/4885ALDH1A1 3742/4885POLB 1230/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | KMT2A 2793/4885ALDH1A1 3742/4885POLB 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.